NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









AviadoBio

AviadoBio

Private
LondonHealthcare & Life Scienceshttps://aviadobio.com/

Last Round

Grant

Mar 31, 2026

Total Funding Raised

$151.89M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

AviadoBio is a biotechnology company that develops innovative gene therapies aimed at transforming the lives of individuals affected by severe neurodegenerative diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

gene therapyprecision gene silencingblood-brain barrierneurodegenerative diseasecapsid technologybiotechRNAivMiXTfR1 CapXgenetic medicinedrug discoverytauopathiesclinical-stage biotechlicensing agreementCNS therapeutics

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

AviadoBio Comparables

Compare AviadoBio with similar companies based on industry and business-model similarity.

AviadoBio comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Coave Therapeutics
84%
Capsida Biotherapeutics
81%
DegenRx B.V.
79%

AviadoBio Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantMar 31, 2026
StrategicOct 8, 2024
Series ADec 2, 2021
SeedApr 1, 2021
SeedDec 1, 2020

Key People

Founding team and executive leadership

Lisa Deschamps

Chief Executive Officer Board Member

Executive Team

Graeme Fielder

Chief Operating Officer

Executive Team

AviadoBio Investors

Notable investors and investment history

Market signals

Structured signals derived from secondary market and firmographic data.

  • Apr 27, 2026

    Combining RNAi platform with TfR1 capsid for CNS gene silencing.

  • Apr 27, 2026

    Presenting drug candidate data at the ASGCT Annual Meeting.

AviadoBio Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

AviadoBio Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about AviadoBio's valuation, stock price, and market status.

Firmographic Details

HeadquartersLondon
Employee Range68
Year Founded2019
Last FundingMar 31, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.